within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR15_AtazanavirAndCobicistat;

model AtazanavirAndCobicistat
  extends Pharmacolibrary.Drugs.ATC.J.J05AR15;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>J05AR15</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Atazanavir/cobicistat is a fixed-dose antiretroviral combination used in the treatment of HIV-1 infection in adults and adolescents. Atazanavir is a protease inhibitor, while cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A enzymes, thereby increasing atazanavir plasma concentrations. This combination is approved for use in various national and international HIV treatment guidelines.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported in healthy HIV-negative adult volunteers following once-daily oral administration of fixed-dose combination tablets under fed conditions.</p><h4>References</h4><ol><li><p>Elliot, ER, et al., &amp; Boffito, M (2019). Pharmacokinetics (PK) of ethinylestradiol/levonorgestrel co-administered with atazanavir/cobicistat. <i>HIV research &amp; clinical practice</i> 20(3) 82–91. DOI:<a href=\"https://doi.org/10.1080/25787489.2019.1638077\">10.1080/25787489.2019.1638077</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31335301/\">https://pubmed.ncbi.nlm.nih.gov/31335301</a></p></li><li><p>Deeks, ED (2014). Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection. <i>Drugs</i> 74(2) 195–206. DOI:<a href=\"https://doi.org/10.1007/s40265-013-0160-x\">10.1007/s40265-013-0160-x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24343782/\">https://pubmed.ncbi.nlm.nih.gov/24343782</a></p></li><li><p>Tittle, V, et al., &amp; Nwokolo, N (2015). Pharmacokinetic and pharmacodynamic drug interactions between antiretrovirals and oral contraceptives. <i>Clinical pharmacokinetics</i> 54(1) 23–34. DOI:<a href=\"https://doi.org/10.1007/s40262-014-0204-8\">10.1007/s40262-014-0204-8</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25331712/\">https://pubmed.ncbi.nlm.nih.gov/25331712</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end AtazanavirAndCobicistat;
